NEWSWIRE
STERIS acquires surgical instrumentation assets from BD for $540 million
STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced on June 20 that the Company has signed a definitive agreement to purchase the surgical instrumentation, laparoscopic instrumentation and steriliza- tion container assets from Becton, Dickinson and Company (NYSE:BDX) (“BD”) for $540 million (“the Transaction”). STERIS antici- pates that the acquisition will qualify for a tax benefit related to tax deductible good- will, with a present value of approximately $60 million. The acquisition includes V. Mueller, Snowden-Pencer and Genesis branded products, which are well-known providers of surgical instruments and steril- ization containers to Healthcare Customers. Annual revenue for these businesses collec- tively for BD’s fiscal year ended September 30, 2023, is projected to be approximately $170 million, with adjusted earnings before interest and taxes of approximately $45 million. “We are pleased to announce the signing of this agreement today, as the brands we are adding will strengthen, complement and expand STERIS’s product offerings within our Healthcare segment. In par- ticular, the focus on the operating room and sterile processing department fits per- fectly with our Healthcare Customers,” said Dan Carestio, President and Chief Executive Officer of STERIS. “We welcome these teams to STERIS and look forward to working together to enhance our value to our Customers.” Under the terms of the agreement, STERIS will purchase surgical instrumentation, laparoscopic instrumentation and steril- ization containers assets from BD at closing. The Transaction will be financed through a combination of debt and cash on hand and is anticipated to close by September 30, 2023, pending customary closing condi- tions and regulatory approval. Management will update the fiscal year 2024 outlook to reflect this Transaction after closing. It is expected to be accretive to adjusted earnings per diluted share in fiscal year 2024. Read on:
https://hpnonline.com/53064069
Gentle cleansers kill viruses as effectively as harsh soaps, study finds
Healthcare professionals often substitute harsh soaps or alcohol-based hand sanitiz- ers with skin-friendly cleansers in order to treat or prevent irritant contact dermati- tis - a common skin disease which causes
red and swollen skin with a dry and dam- aged surface.
During the COVID-19 pandemic, inci- dence and severity of the disease amongst healthcare professionals increased from 20% to 80%.
Despite the widespread use of gentle cleansing products for handwashing, there has been limited evidence to show the anti- viral efficacy of the products to prevent the spread of viruses such as human coro- navirus, herpes simplex virus, norovirus and influenza. Scientists from the University of Sheffield’s Sheffield Dermatology Research (SDR) group tested multiple handwash products as part of the study. These included anti- bacterial soap, natural soap, foam cleans- ers and bath wash products, with the team investigating their ability to kill both envel- oped viruses; such as human coronavirus and influenza, which have an additional layer of structural protection; compared to non-enveloped viruses, such as norovirus and adenovirus. The findings, published in the journal Frontiers Virology, show gentle cleansers were effective in killing enveloped viruses, but non-enveloped viruses displayed resis- tance against skin-friendly cleansers, as well as harsh soaps. Read on:
https://hpnonline.com/53063471
Study provides new details about Long COVID symptoms Initial findings from a study of nearly 10,000 Americans, many of whom had COVID- 19, have uncovered new details about long COVID, the post-infection set of conditions that can affect nearly every tissue and organ in the body. Clinical symptoms can vary and include fatigue, brain fog, and dizziness, and last for months or years after a person has COVID-19. The research team, funded by the National Institutes of Health, also found that long COVID was more common and severe in study participants infected before the 2021 Omicron variant. The study, published in JAMA is coor- dinated through the NIH’s Researching COVID to Enhance Recovery (RECOVER) initiative, a nationwide effort dedicated to understanding why some people develop long-term symptoms following COVID-19, and most importantly, how to detect, treat, and prevent long COVID. The research- ers hope this study is the next step toward potential treatments for long COVID, which affects the health and wellbeing of millions of Americans. Read on:
https://hpnonline.com/53061887
FAST STATS U.S. Lung Cancer Statistics
In the U.S. in 2020:
197,453 new lung cancers were reported
136,084 people died from lung cancer
Males had higher rates of getting and dying from lung cancer than females From 2016-2020,
45% of all lung cancers were diagnosed at a distant stage
27% were found at the localized stage 23% were found at the regional stage 5% were identified as unknown
26% of lung cancer patients who were diagnosed from 2013 to 2019 had not died from their cancer 5 years later
Among people diagnosed with lung cancer from 2015 to 2019,
alive on January 1, 2020
2020 cancer incidence was lower than in 2019, and this may have been because of
the effect the COVID-19 pandemic had on cancer screening, diagnosis, and reporting to some central cancer registries in 2020
Source:
https://www.cdc.gov/cancer/uscs/about/stat-bites/ stat-bite-lung.htm
Photo credit: SciePro |
stock.adobe.com
hpnonline.com • HEALTHCARE PURCHASING NEWS • August 2023 5 425,015 were still
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
